MS Pharma (IFC-37564)

Countries
  • Jordan
Where the impacts of the investment may be experienced.
Financial Institutions
  • International Finance Corporation (IFC)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Active
Bank Risk Rating
B
Risk rating varies among banks and may refer only to the particular investment and not to the risk for the project as a whole. Projects marked 'U' have an 'Unknown' risk rating at the time of disclosure.
Voting Date
Apr 6, 2017
The estimate day the bank will vote on a proposed investment. The decision dates may change, so review updated project documents or contact the EWS team.
Borrower
MS PHARMA VENTURES HOLDING WLL
The holder of the loan, grant, or other investment.
Sectors
  • Education and Health
The service or industry focus of the investment. A project can have several sectors.
Investment Type(s)
Equity
The categories of the bank investment: loan, grant, etc.
Investment Amount (USD)
$ 50.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Bank Documents
Primary Source

Original disclosure @ IFC website

Updated in EWS Sep 23, 2017

Disclosed by Bank Apr 10, 2017


Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description
The proposed project involves an IFC equity investment of up US$ 50 million in MS Pharma Ventures Holding W.L.L. (“MS-Pharma” or “the group”), a Jordan based generic pharmaceutical manufacturer and distributor across the Middle East and North Africa (MENA) region. The investment will allow MS-Pharma to continue increasing its geographical reach in the region mainly via mergers and acquisitions of manufacturing assets in new markets or construction of new facilities (Saudi Arabia). Short-term plans include upgrading the MS-Pharma injectable plant (MSI) in Jordan and MS Pharma Injectable plant in Turkey (acquired in 2012 and 2016 respectively), expanding the El Kendi manufacturing facility in Algeria to double production capacity, and pursue acquisition of product portfolio/marketing authorizations to accelerate market entry (Egypt). In Saudi Arabia the group has acquired in the private market an area, within a pharmacological industrial park, where it plans to build a production facility and worker accommodations. In Algeria, the group, via the controlled El Kendi Pharma Manufacturing, will expand its production by building, within the same property where the existing plant is located, a new 4-story facility with a 1,750-m2footprint and a total floor space on 7,000 m2.
Investment Description
  • International Finance Corporation (IFC)
Contact Information
ACCOUNTABILITY MECHANISM OF IFC The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org. You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org/